PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Pathology Diagnostics Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New in Situ mRNA Detection Method Accurately Measures PD-L1 mRNA in Early Stage Breast Cancer - Solving the problem of PD-L1 measurement using antibody based techniques - PathologyDiagnostics.com
New in Situ mRNA Detection Method Accurately Measures PD-L1 mRNA in Early Stage Breast Cancer

 

NewswireToday - /newswire/ - Cambridge, Cambridgeshire, United Kingdom, 2014/07/25 - Solving the problem of PD-L1 measurement using antibody based techniques - PathologyDiagnostics.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A new molecular analysis tool has been used to detect the level of an important target for immunotherapy in early-stage breast cancers, researchers at Yale University report in the journal Clinical Cancer Research (Clin Cancer Res; 20(10); 2773 82).

Blockade of the PD-1/PD-L1 pathway is an important axis for new oncology therapies against melanoma, breast, ovarian, colorectal and other cancers. Levels of tumour PD-L1 expression are indicative of tumour survival and response to treatment. Development of accurate reproducible PD-L1 test is imperative in the pharmaceutical and R&D healthcare setting. However measurement of PD-L1 protein levels is limited by lack of standardisation of tests and variable performance of antibodies.

The new diagnostic test, developed in the Rimm laboratory at Yale University Department of Pathology using RNAScope, measures the amount of PD-L1 mRNA in cancer tissues. It is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. In their published study analysing PD-L1 mRNA in 636 breast cancers, nearly 60% of tumours were positive for PD-L1 mRNA. Furthermore, PD-L1 mRNA levels are significantly associated with tumour infiltrating lymphocytes, breast cancer ER negative status and improved recurrence free survival.

These observations support the evaluation of PD-1/PD-L1 targeted therapies in breast cancer and offer new hope for the development of a robust clinical test for patient stratification.

Source: K. A. Schalper, V. Velcheti, D. Carvajal, H. Wimberly, J. Brown, L. Pusztai, D. L. Rimm. In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas. Clinical Cancer Research, 2014; 20 (10): 2773 DOI: 10.1158/1078-0432.CCR-13-2702

Pathology Diagnostics Ltd (pathologydiagnostics.com) is an independent GCLP accredited histopathology research organisation delivering high-quality tissue laboratory & diagnostics services to industry Research & Development scientists engaged in drug and biomarker development.

Specialising in the provision of clinical diagnostics and quantitative image analysis on human tissues for studies ranging from early discovery to clinical trials, Pathology Diagnostics offers a range of services from traditional histopathology techniques to advanced digital pathology, whole slide scanning, central biorepository services and quantitative image analysis of biomarkers.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Pathology Diagnostics Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New in Situ mRNA Detection Method Accurately Measures PD-L1 mRNA in Early Stage Breast Cancer

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Marketing Officer - PathologyDiagnostics.com 
+44(0)12 2385 1354 as[.]pathologydiagnostics.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Pathology Diagnostics Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Pathology Diagnostics Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)